Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial. (2023)

First Author: Waters L
Attributed to:  Blood borne viruses funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/cid/ciac827

PubMed Identifier: 36259527

Publication URI: http://europepmc.org/abstract/MED/36259527

Type: Journal Article/Review

Volume: 76

Parent Publication: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Issue: 5

ISSN: 1058-4838